PULMOPHARMA ApS: Financial statements 2020
CVR: 36428023
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
PULMOPHARMA ApS (CVR 36428023) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -1,060 and a net result of DKK -18,958 compared with DKK -25,905 the year before. Equity in the 2020 report amounted to DKK -395,182. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,060
- Profit/Loss
- DKK -18,958
- Equity
- DKK -395,182
- Total Assets
- DKK 79,620
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -1 t. | -19 t. | -395 t. | 1 |
| 2019 | - | -9 t. | -26 t. | -376 t. | - |
| 2018 | - | -292 t. | -224 t. | -350 t. | - |
| 2017 | - | -120 t. | -123 t. | -126 t. | - |
| 2016 | - | 0 | 0 | -3 t. | - |
Official annual report
How creditworthy is PULMOPHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
PULMOPHARMA ApS has published its annual report for 2019. Gross profit came to DKK -8,735, and the net result was DKK -25,905.
About PULMOPHARMA ApS
PULMOPHARMA ApS is a Danish company of the type Anpartsselskab based in Ebeltoft, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named PULMOPHARMA IVS. The management consists of Dan Mønster Nielsen. The board consists of Torben Ballegaard Sørensen (chair), Dan Mønster Nielsen, Per Bendix Jeppesen and Peter Frithjof Bang. The company's owners include PETER BANG HOLDING ApS, LARS NYENSTAD ApS and BENDIX-HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -49,353 and a net result of DKK -49,353 compared with DKK -20,499 the year before. Equity in the 2025 report amounted to DKK 11,436,934.